Sleep and breathing disorders
Oral presentation
Emerging insights in prognostic aspects and positive airway pressure treatment for obstructive sleep apnoea
Clinical
Methods :
Cell and molecular biology, Epidemiology, General respiratory patient care, Physiology, Public health
14:15
Late Breaking Abstract - A randomized, double-blind, placebo controlled, dose-finding trial of sulthiame in obstructive sleep apnea
J. Hedner(Göteborg, Sweden)
COI
1
OA5433
14:20
Nightly variation in OSA severity and next day blood pressure
B. Lechat(Adelaide, Australia)
COI
2
OA5434
14:25
Sleep apnea–specific pulse-rate response, cardiovascular risk and response to positive airway pressure.
M. Blanchard(Sainte-Gemmes-sur-Loire, France)
COI
3
OA5435
14:30
The impact of obstructive sleep apnea on the circadian rest-activity rhythm: a cross-sectional analysis of the ELSA-Brasil cohort
A. D. S. Targa(Lleida, Spain)
COI
4
OA5436
14:35
Differences in power consumption of continuous positive airway pressure (CPAP) devices
C. Bianquis(Saint-Prix, France)
COI
5
OA5437
14:40
CPAP effects on blood pressure in different OSA phenotypes – a meta-analysis
L. Benning(Zurich, Switzerland)
COI
6
OA5438
14:45
Association of positive airway pressure adherence with the burden of antihypertensive medications in hypertensive patients with sleep apnoea: data from the IRSR Pays de la Loire Sleep Cohort.
D. Jaffuel(Puimisson, France)
COI
7
OA5439
14:50
Self-efficacy is an independent predictor of one-year PAP adherence trajectories
S. Bailly(Grenoble, France)
COI
8
OA5440
14:55
CPAP effect on energy balance, chronotype, hormone, and body composition: a randomized controlled trial
P. Lee(Taipei, Taiwan)
COI
9
OA5441
15:00
Effect of CPAP on circulating levels of MPO and MMP-9 in adults with coronary artery disease and obstructive sleep apnoea: the RICCADSA randomized controlled trial
Y. Peker(Istanbul, Turkey)
COI
10
OA5442
15:05
Discussion and Q&A
11
OA5443
. . .
